Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New flu pill for kids shows promise in early trial

NCT ID NCT06656026

Disease control Sponsor: Guangdong Raynovent Biotech Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new flu medicine called ZSP1273 in 72 children aged 2 to 17 with influenza A. The goal was to see how safe it is, how the body processes it, and whether it helps reduce flu symptoms. The trial took place in China and has already been completed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ZSP1273 granules
What this could lead to
If successful, this could lead to a new treatment option for children with influenza A, potentially shortening illness duration and reducing symptoms.
What could go wrong
This is an early-phase trial with only 72 participants, so results may not apply broadly. The drug may not prove more effective than existing flu treatments, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

72 people

The number who actually took part.

Started

Nov 2024

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects and their guardians who are able to understand the study and comply with all study procedures, and willing to provide written informed consent/assent prior to the predose examinations appropriately. 2. Male or female subjects aged ≥ 2 to ≤17 years at the time of signing the informed consent form. 3. Subjects with a diagnosis of influenza virus infection confirmed by all of the following: * Positive rapid antigen test (RAT) for influenza with nasal or throat swabs; * The time interval between the onset of symptoms and enrollment is 72 hours or less; * Fever ≥ 38ºC (axillary temperature); and at least one following respiratory symptoms associated with influenza virus infection is present Exclusion Criteria: 1. Subjects with severe influenza virus infection； 2. Subjects with any medical history in gastrointestinal that interferes with the absorption of drugs； 3. Immunodeficiency,including malignant tumor,organ or marrow transplant,human immunodeficiency virus \[HIV\] infection,or patients receiving immunosuppressant therapy 3 months prior to enrollment； 4. Have received any other investigational products within 3 months prior to dosing； 5. Positive urine pregnancy test； 6. Subjects with concurrent infections requiring antimicrobial therapy； 7. Subjects who are considered inappropriate for the study by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

swine influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Influenza A

Contacts and locations

Locations

  • The First Affiliated Hospital Of Guangzhou Medical University

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.